Lifeboat Foundation

Although UBTech is leaving 10% of work for humans in management, other AI tech is being specifically developed for that niche: OpenAI’s new framework, Swarm, allows AI agents to collaborate and independently execute complex tasks, potentially boosting business efficiency.

Artificial intelligence agents are everywhere, quietly reshaping industries and automating tasks we didn’t think possible a few years ago. Unlike basic automation, these AI agents can handle complex jobs, think independently and learn from their environment. The result? Healthcare, finance and logistics businesses are seeing rapid gains in efficiency — and, in some cases, doing away with manual work altogether.

What are AI agents exactly? They’re software programs that carry out specific tasks without constant supervision. Whether handling customer requests, diagnosing medical conditions or predicting market trends, AI agents are versatile workhorses. Instead of waiting for humans to input every command, these agents operate autonomously, reacting to real-time data and adjusting their actions accordingly.

Continue reading “AI Explained: AI Agents Are Quietly Taking Over Everyday Tasks” »

This study presents the development and characterization of a novel nanocomposite wound dressing material based on polylactic acid (PLA) nanofibers incorporating chitosan nanocapsules loaded with chamomile extract and cellulose nanoparticles.

Asadzadeh, F., Ghorbanzadeh, S., Poursattar Marjani, A. et al. Sci Rep 14, 22,336 (2024). https://doi.org/10.1038/s41598-024-72398-9

Download citation.

Continue reading “Assessing polylactic acid nanofibers with cellulose and chitosan nanocapsules loaded with chamomile extract for treating gram-negative infections” »

The research focuses on “cellular senescence,” a process where cells stop dividing and enter a state associated with chronic inflammation and aging.

This cellular state, known as the senescence-associated secretory phenotype (SASP), involves the secretion of inflammatory proteins that accelerate aging and disease, such as dementia, diabetes, and atherosclerosis.

How do plants and fungi communicate with each other? This is what a recent study published in Molecular Cell hopes to address as an international team of researchers investigated the “language” conducted between plants and fungi that enables fungi growth. This study holds the potential to help scientists and farmers better understand how to fight disease-causing fungi by growing crops with greater resilience and adversity.

“As we begin to understand how plants and fungi communicate, we will better understand the complexities of the soil ecosystem, leading to healthier crops and improving our approach to biodiversity,” said Dr. Shelley Lumba, who is an assistant professor in the Department of Cell and Systems Biology at the University of Toronto and a co-author on the study.

For the study, the researchers examined strigolactone (SL), which is a class of plant hormones and signaling molecules responsible for plant development, with the team focusing on how SL influences fungi growth and development by testing SL with yeast. In the end, the researchers found that SL triggered certain genes called “PHO” that are responsible for phosphate metabolism, along with finding that plants release SL when they are low on phosphate, forcing the yeast to alter the amount of phosphate consumes by triggering the protein, Pho84.

Australian, American and British researchers conducted a prospective analysis of light levels in almost 89 thousand people and concluded that more light exposure at night and less during the day are associated with an increased risk of death from all causes.

Light enhances or disrupts circadian rhythms, depending on the timing of exposure. Circadian disruption contributes to poor health outcomes that increase mortality risk. Whether personal light exposure predicts mortality risk has not been established. We therefore investigated whether personal day and night light, and light patterns that disrupt circadian rhythms, predicted mortality risk. UK Biobank participants (N = 88,905, 62.4 ± 7.8 y, 57% female) wore light sensors for 1 wk. Day and night light exposures were defined by factor analysis of 24-h light profiles. A computational model of the human circadian pacemaker was applied to model circadian amplitude and phase from light data. Cause-specific mortality was recorded in 3,750 participants across a mean (±SD) follow-up period of 8.0 ± 1.0 y.

Would you like to see more applications for Neuralink in the future? Share your thoughts in the comments.

Elon Musk’s brain technology startup, Neuralink, reported that its implant is functioning well in a second trial patient, identified as Alex. This implant is designed to help paralyzed patients control digital devices through thought alone. Unlike the first patient, Noland Arbaugh, who experienced thread retraction issues post-surgery, Alex has not faced similar problems. Neuralink implemented new measures to prevent such complications, including reducing brain motion during surgery. Both patients have been able to use the implant to perform tasks like playing video games, browsing the internet, and even designing 3D objects.

Women worldwide could see better treatment with new AI technology, which enables better detection of damaged cells and more precisely predicts the risk of getting breast cancer, shows new research from the University of Copenhagen.

Breast cancer is one of the most common types of cancer. In 2022, the disease caused 670,000 deaths worldwide. Now, a new study from the University of Copenhagen shows that AI can help women with improved treatment by scanning for irregular-looking cells to give better risk assessment.

The study, published in The Lancet Digital Health, found that the AI technology was far better at predicting the risk of cancer than current clinical benchmarks for breast cancer risk assessment.

An achievement that was deemed impossible has successfully become accomplished. For the first time in history, DNA can be edited. One of the goals is to be able to get rid of genetic diseases. This whole concept in genomic science has opened up a whole new revolutionary way of dealing with such critical health issues. There is a possibility that illnesses that were once incurable have a chance to be curable.

MedlinePlus provides a definition and states that a collection of tools known as genome editing, or gene editing, allows researchers to alter an organism’s DNA. These technologies enable the addition, deletion, or modification of genetic material at specific genomic regions. A person’s DNA can be altered through gene editing to fix mistakes that lead to illnesses.

CRISPR-Cas9, short for CRISPR-associated protein 9 and clustered regularly interspaced short palindromic repeats, is a well-known example as one of the approaches used and developed by scientists to edit DNA. The scientific community is very excited about the CRISPR-Cas9 system since it is more accurate, efficient, quicker, and less expensive than existing genome editing techniques.

Despite its almost perfect anti-aging profile, rapamycin exerts one significant limitation – inappropriate physicochemical properties. Therefore, we have decided to utilize virtual high-throughput screening and fragment-based design in search of novel mTOR inhibiting scaffolds with suitable physicochemical parameters. Seven lead compounds were selected from the list of obtained hits that were commercially available (4, 5, and 7) or their synthesis was feasible (1, 2, 3, and 6) and evaluated in vitro and subsequently in vivo. Of all these substances, only compound 3 demonstrated a significant cytotoxic, senolytic, and senomorphic effect on normal and cancerous cells. Further, it has been confirmed that compound 3 is a direct mTORC1 inhibitor. Last but not least, compound 3 was found to exhibit anti-SASP activity concurrently being relatively safe within the test of in vivo tolerability. All these outstanding results highlight compound 3 as a scaffold worthy of further investigation.

GRAPHICAL ABSTRACT